JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salzman, N. P.
Right arrow Articles by Brodie, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salzman, N. P.
Right arrow Articles by Brodie, B. B.
Journal of Pharmacology And Experimental Therapeutics, Vol. 118, Issue 1, 46-54, 1956
Copyright © 1956 by American Society for Pharmacology and Experimental Therapeutics

PHYSIOLOGICAL DISPOSITION AND FATE OF CHLORPROMAZINE AND A METHOD FOR ITS ESTIMATION IN BIOLOGICAL MATERIAL

Norman P. Salzman 1 and Bernard B. Brodie 1

1 Laboratory of Chemical Phmacology, National Heart Institute, National Institutes of Health, Public Health Service, U. S. Department of Health, Education and Welfare, Bethesda, Md.

A method is described for the estimation of chlorpromazine and chlorpromazine sulfoxide in biological material.

In the dog, chlorpromazine is metabolized almost completely but, partly because of its extensive localization in various tissues, especially brain, relatively slowly. At least three metabolic products are formed.

The main metabolic product has been isolated from the urine of dogs receiving chlorpromazine and identified as the sulfoxide. It is also formed in man. The sulfoxide undergoes metabolism to an unidentified product.

The sulfoxide although less active than chlorpromazine exerts a sedative action at dosage levels that do not produce postural hypotension in dog or man.

Submitted on April 27, 1956




This article has been cited by other articles:


Home page
 ScienceHome page
R. Pearson, A. Manian, J. Harcus, D Hall, and E. Hewlett
Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani
Science, July 23, 1982; 217(4557): 369 - 371.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
M. WOLLEMANN and L. ZOLTAN
Cholinesterase Activity of Cerebral Tumors and Tumorous Cysts
Arch Neurol, February 1, 1962; 6(2): 161 - 167.
[Abstract] [PDF]

Home page
 ScienceHome page
A. H. CONNEY, J. R. GILLETTE, J. K. INSCOE, E. R. TRAMS, and H. S. POSNER
Induced Synthesis of Liver Microsomal Enzymes Which Metabolize Foreign Compounds
Science, November 27, 1959; 130(3387): 1478 - 1479.
[Abstract] [PDF]

Home page
 ScienceHome page
J. R. FOUTS and R. H. ADAMSON
Drug Metabolism in the Newborn Rabbit
Science, April 3, 1959; 129(3353): 897 - 898.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
N. M. KAPLAN
Hypotension as a Complication of Promazine Therapy
Arch Intern Med, February 1, 1959; 103(2): 219 - 223.
[Abstract] [PDF]

Home page
 ScienceHome page
D. J. CAVANAUGH
Oxidation of Chlorpromazine by Peroxidase and Catalase
Science, May 24, 1957; 125(3256): 1040 - 1041.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1956 by the American Society for Pharmacology and Experimental Therapeutics.